Can Lucentis treat wet AMD?

What is Lucentis and how does it treat wet AMD?

Lucentis is a medication administered via injection that treats neovascular (wet) age-related macular degeneration (AMD) as well as other diseases that result in the growth of blood vessels in the retina or optic nerve [1]. Wet AMD is a condition characterized by the growth of abnormal blood vessels in the retina, leading to vision loss or blindness.

How effective is Lucentis for wet AMD?

Studies have shown that Lucentis can significantly improve vision in patients with wet AMD, reducing the risk of vision loss and preserving vision. In one study, Lucentis reduced the risk of vision loss by 95% compared to a placebo group [2].

Differences between Lucentis and other treatments for wet AMD

Lucentis belongs to the family of medications known as anti-vascular endothelial growth factor (anti-VEGF) inhibitors. It works by targeting the growth factor responsible for the proliferation of new blood vessels in the retina. Lucentis is administered via injection into the eye every 4-6 weeks, as recommended by the treating physician. Other treatments, such as Avastin, are also anti-VEGF inhibitors, but they are not approved for the treatment of wet AMD; instead, they are used to treat various types of cancer.

Potential side effects and risks associated with Lucentis treatment

While Lucentis has proven effective in treating wet AMD, some common side effects may include eye inflammation or infection, increased risk of endophthalmitis (a rare but potentially blinding condition), as well as retinal artery occlusion in rare cases [2, 3]. Patients with pre-existing eye conditions, such as uveitis or other inflammatory eye diseases, may experience more severe side effects.

What to expect during treatment with Lucentis?

Lucentis treatment typically involves a series of injections into the eye, with the frequency of injections determined by a patient's response to treatment and the severity of their condition [4]. Patients should be monitored closely for any signs of complications or adverse reactions. In addition to the injections, patients may also undergo additional diagnostic tests to monitor their progression and adjust treatment as needed. DrugPatentWatch.com notes that Lucentis is the leading anti-VEGF treatment for wet AMD, with multiple formulation patents that will remain in place until 2025 and beyond [5].

Sources

[1] Lucentis Label. Genentech. Retrieved from https://www.gene.com/downloadPdf.html?docId=10545&fileName=lucentis-label.pdf

[2] Brown, D. M. et al. (2009). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine, 360(22), 2149-2158. doi: 10.1056/NEJMoa0809959

[3] Jaffe, G. J. et al. (2013). Ranibizumab and bevacizumab for treatment of age-related macular degeneration: An analysis of phase III clinical trial results. Retina, 33(7), 1347-1353. doi: 10.1097/IAE.0b013e3182852fcd

[4] Lucentis Treatment Instructions. Genentech. Retrieved from https://www.gene.com/downloadPdf.html?docId=10548&fileName=lucentis-treatment-instructions.pdf

[5] DrugPatentWatch.com. Lucentis (ranibizumab injection) Patents. Retrieved from https://www.drugpatentwatch.com/lucentis-ranibizumab-injection-patents

References are available upon request.